OMCAP (omeprazole) reduces gastric acid secretion through a highly selective mechanism of action. It produces specific dose dependent inhibition of the enzyme H+, K -ATPase (the ‘proton pump’) in the parietal cell. As this action inhibits the final stage of gastric acid formation, there is effective inhibition of both basal and stimulated acid secretion irrespective of the stimulus to acid formation. Omeprazole has no effect on acetylcholine or histamine receptors and no clinically significant pharmacodynamic effects have been observed other than those explained by the effect of omeprazole on acid secretion. The onset of action is rapid and reversible. Control of gastric acid secretion is achieved with once daily dosing.
OMCAP is indicated for:
Treatment of duodenal ulcer
Treatment of gastric ulcer
Treatment of reflux oesophagitis
Management of Zollinger-Ellison Syndrome
Explore more products from our portfolio
